- Home
- AIRT vs GANX Comparison
AIRT vs GANX Comparison
Compare AIRT & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRT | GANX |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.1M | 88.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AIRT | GANX |
|---|---|---|
| Price | $33.95 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 13.1K | ★ 485.3K |
| Earning Date | 02-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1393.72 | 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $286,834,000.00 | $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.98 | N/A |
| 52 Week Low | $18.35 | $1.53 |
| 52 Week High | $35.00 | $4.34 |
Technical Indicators
Market Signals| Indicator | AIRT | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 44.18 |
| Support Level | $20.19 | $1.64 |
| Resistance Level | $34.74 | $2.22 |
| Average True Range (ATR) | 1.80 | 0.13 |
| MACD | 0.24 | -0.03 |
| Stochastic Oscillator | 100.00 | 5.08 |
Price Performance
Historical ComparisonAbout AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include overnight air cargo, ground support equipment, commercial aircraft, engines and parts, digital solutions, and regional airline. The company generates maximum revenue from the overnight air cargo segment.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.